Patent Portfolio

Search by tag

New

• 

  Drug Discovery / Therapy

  AJ270

  Composition and pharmaceutical composition

  The present invention relates to a composition and a pharmaceutical composition for promoting myocardial differentiation used for prevention and/or treatment of heart disease, and which is a composition and a pharmaceutical composition containing miR-132 as an active ingredient. The composition exhibiting a high function for promoting the differentiation of myocardial cells and being effective for improving cardiac function after suffering from a heart disease.

  Pub. No.

  WO2022/202930

  Pub. date

  2022/9/29

• 

  Drug Discovery / Therapy

  • Nerve (Neuron)

  AJ269

  Nerve cell degeneration inhibitor

  The present invention relates to a nerve cell degeneration inhibitor. The present invention provides an agent that is highly effective in inhibiting the formation of RNA foci and DPRs for neurodegenerative diseases associated with abnormal expansion of the G4C2 repeat of the C9orf72 gene, and can be used as a prophylactic or therapeutic agent for said diseases.

  Pub. No.

  WO2021/193982

  Pub. date

  2021/9/30

• 

  Drug Discovery / Therapy

  • Nerve (Neuron)

  AJ268

  Motor neuron degeneration inhibitor

  The present invention relates to agents (medicines, pharmaceutical compositions) containing compounds that has an inhibitory activity on motor neuron degeneration (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy) and is useful for treating motor neuron disorder and the like.

  Pub. No.

  WO2021/075477

  Pub. date

  2021/4/22

• 

  Reprogramming

  AJ261

  Method for producing pluripotent stem cells

  Provided is a method for producing pluripotent stem cells by introducing mRNA of a reprograming factor gene into blood cells. The method being characterized by including a step 1 for introducing mRNA of a reprogramming factor gene into somatic cells, and a step 2 for culturing the somatic cells into which the mRNA was introduced, and also being characterized in that, in step 1, the mRNA of the reprogramming factor gene is introduced into the somatic cells in the presence of laminin having an α5 chain or a fragment thereof having integrin-binding activity.

  Pub. No.

  WO2022/244670

  Pub. date

  2022/11/24

• 

  Drug Discovery / Therapy

  • Nerve (Neuron)

  AJ260

  Drug kit and method for rebuilding damaged neural pathways

  The present invention provides a drug kit for rebuilding a damaged neural pathway, wherein the drug kit comprises a first formulation comprising axonal elongation-inducing protein, nucleic acid encoding said protein, or a vector that expressibly contains DNA encoding said protein that induces axonal elongation of tranplanted neuronal cells. The present invention also provides a method for rebuilding a damaged neural pathway in a patient, the method comprising the administration of the first formulation of this drug kit.

  Pub. No.

  WO2022/234843

  Pub. date

  2022/11/10

• 

  Others

  AJ259

  Method for inducing primed pluripotent stem cells into naive pluripotent stem cells, method for manufacturing naive pluripotent stem cells, kit for naive pluripotent stem cell induction, and naive pluripotent stem cell inducing agent

  Provided is a method for inducing primed pluripotent stem cells into naive pluripotent stem cells by the addition of an AMP kinase activator into a culture medium and a method for inducing primed pluripotent stem cells into naive pluripotent stem cells, that includes a step in which the primed pluripotent stem cell p38 MAP kinase pathway is activated. Also provided are a naive pluripotent stem cell induction kit for these methods and a naive pluripotent stem cell inducing agent.

  Pub. No.

  WO2022/191335

  Pub. date

  2022/9/15

• 

  Drug Discovery / Therapy

  AJ258

  Method for proliferating cardiomyocytes, method for producing cardiomyocytes, and cardiomyocyte proliferating agent

  The invention relates to a method for proliferating cardiomyocytes using one or more compounds selected from the group consisting of ALK inhibitors, cytochrome P450 omega hydroxylase inhibitors, and fatty acid synthesis inhibitors, and provided are a method for proliferating cardiomyocytes, a method for producing cardiomyocytes, and a cardiomyocyte proliferating agent capable of contributing to cardiac regenerative medicine.

  Pub. No.

  WO2022/191130

  Pub. date

  2022/9/15

• 

  Drug Discovery / Therapy

  AJ257

  Artificial collecting duct organoid having cystic structure

  Provided is a method for producing an artificial collecting duct organoid having a cystic structure formed by a cell population containing cells expressing markers specific to collecting duct principal cells from an autosomal dominant polycystic kidney disease (ADPKD)-specific ureteric bud tip cell, a method for producing a collecting duct cyst model, and a method for cultivation of produced artifical collecting duct organoids.

  Pub. No.

  WO2022/210968

  Pub. date

  2022/10/6

• 

  Maintenance / Propagation

  AJ256

  Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids

  This invention relates to a medium for culturing and expanding nephron progenitor cells while retaining their differentiation potential, a method for culturing and expanding nephron progenitor cells using the aforesaid medium, and a method for producing renal organoids from aforesaid nephron progenitor cells. The nephron progenitor cells and renal organoids generated by this invention method may be applicable to the treatment or prevention of renal disease.

  Pub. No.

  WO2022/149616

  Pub. date

  2022/7/14

• 

  Drug Discovery / Therapy

  AJ255

  Therapeutic agent for x-linked sideroblastic anemia

  The present invention provides a pharmaceutical composition for treating X-linked sideroblastic anemia, the composition comprising a demethylating agent, in particular, 5-azacitidine or a derivative thereof; and normal erythroid cells that are differentiated and induced from iPS cells derived from a patient with X-linked sideroblastic anemia in the presence of a demethylating agent.

  Pub. No.

  WO2022/145144

  Pub. date

  2022/7/7

• 

  Drug Discovery / Therapy

  AJ253

  Information processing method, information processing device, and program

  An information processing method according to the present invention includes: a step 1 for detecting a first SNP, which is a mutation of an Alzheimer's disease-related gene, in a genomic DNA sample derived from a subject; and a step 2 for determining, from the first SNP, whether the subject will develop Alzheimer's disease by using a machine learning model that was trained on the basis of a plurality a training datasets labeled with information relating to the development of Alzheimer's disease for a second SNP, which is a mutation of the Alzheimer's disease-related gene detected in a genomic DNA sample derived from a patient who has developed Alzheimer's disease.

  Pub. No.

  WO2022/220236

  Pub. date

  2022/10/20

• 

  Differentiation

  AJ207

  Method for producing cartilage tissue from pluripotent stem cell

  To provide a method for producing cartilage tissue from a pluripotent stem cell by using serum-free culture medium, and a medicine containing cartilage tissue produced by the method. The cartilage tissue produced by the method of the present invention can be suitably used for cartilage regenerative medicine.

  Pub. No.

  JP2020-115771

  Pub. date

  2020/8/6